Fax: (713) 745-1163
Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response
Article first published online: 21 OCT 2005
Copyright © 2005 American Cancer Society
Volume 104, Issue 11, pages 2365–2372, 1 December 2005
How to Cite
Rohatgi, P., Swisher, S. G., Correa, A. M., Wu, T.-T., Liao, Z., Komaki, R., Walsh, G. L., Vaporciyan, A. A., Rice, D. C., Roth, J. A. and Ajani, J. A. (2005), Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer, 104: 2365–2372. doi: 10.1002/cncr.21439
- Issue published online: 18 NOV 2005
- Article first published online: 21 OCT 2005
- Manuscript Accepted: 31 DEC 2004
- Manuscript Revised: 1 NOV 2004
- Manuscript Received: 7 SEP 2004
- Bristol-Myers Squibb Oncology
- Pfizer Oncology
- Rivercreek Foundation
- Smith, Cantu, and Dallas families
- preoperative chemoradiation;
- pathologic complete response (pathCR)
The purpose of the current study was to test the hypothesis that a lower clinical TNM stage is associated with a higher rate of pathologic complete response (pathCR) in patients with esophageal carcinoma receiving preoperative chemoradiotherapy and to determine whether outcome after pathCR is related to clinical stage or treatment.
Clinical parameters and surgical specimens of patients with esophageal carcinoma undergoing preoperative chemoradiotherapy were analyzed to identify predictors of pathCR. In patients with pathCR, predictors of overall survival (OS), disease-free survival (DFS), and distant recurrence were studied.
Sixty-nine (29%) of 235 patients achieved pathCR. In patients with American Joint Committee on Cancer (AJCC) Stage II carcinoma, the proportion achieving pathCR was significantly larger than that achieving <pathCR (65% vs. 35%; P = 0.03). The proportion of patients who received induction chemotherapy was higher in the pathCR group than in the <pathCR group (54% vs. 46%; P = 0.05). However, neither TNM classification, primary tumor location, histologic type, gender, therapy sequence, or radiation dose (45 grays [Gy] vs. 50.4 Gy) were found to have any influence on OS or DFS. The median OS from pathCR was significantly longer than that from <pathCR (133 mos vs. 34 mos; P = 0.002). Similarly, DFS was longer in the pathCR group than in the <pathCR (P = 0.001).
Patients with clinical AJCC Stage II esophageal carcinoma are more likely to achieve a pathCR after preoperative chemoradiotherapy than are those with Stage III carcinoma. Chemoradiotherapy as primary therapy for patients with Stage I esophageal carcinoma warrants investigation as a means to preserve their esophagus. Cancer 2005. © 2005 American Cancer Society.